Cosmo Energy Holdings (5021) · InitiativeDropped
Development of ALA Drug Substances and Formulations for Pharmaceutical Use
First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2019.
4entries
4years
0from disclosures
How it moved
Same theme, other companies
R&D and Global Business Expansion of 5-ALA ProductsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2019DroppedAnnual report
「neo ALA, which was accounted for under the equity method in the previous consolidated fiscal year, was excluded from the scope of equity-method accounting in the current consolidated fiscal year because all of its shares were sold.」
All shares held in neo ALA, which was responsible for developing ALA active pharmaceutical ingredients and formulations, were sold, and the company was excluded from the scope of equity-method accounting. - FY2018RestatedAnnual report
「neo ALA engages in the manufacture and sale of ALA-related products.」
The development, manufacture and sale of ALA-related products and active pharmaceutical ingredients and formulations for pharmaceuticals continued. - FY2017RestatedAnnual report
「Development, manufacturing and sales of ALA products; development of ALA active pharmaceutical ingredients and formulations」
The company continues to describe neo ALA's business as the development, manufacture and sale of ALA products and active pharmaceutical ingredients and formulations for pharmaceuticals. - FY2016First statedAnnual report
「The company conducts R&D aimed at manufacturing and selling ALA active pharmaceutical ingredients and formulations.」
In addition to obtaining approval for an intraoperative diagnostic agent for malignant glioma, the company is conducting clinical trials for mitochondrial disease and anemia caused by cancer chemotherapy.